“目前我国儿童占总人口20%以上，但儿童药品紧缺。国内市场90%药品无适用于儿童的剂型，部分特殊药品甚至供应短缺。”在日前于北京举行的儿童用药问题专题研讨会上，专家建议，政府可以对必要的儿童药品实行补贴政策，建立完善的合理用药机制。

"At present our country children's total population 20%,But children drug shortage.The domestic market 90% drug no suitable for children's dosage form,Part of the special medicine and even supply shortages."In the recently held in Beijing children's drug problem in the seminars,Experts suggest,The government can necessary to children's drug policy subsidies,Establish a perfect mechanism of rational drug use.

儿童药品市场巨大 Children's drug huge market

　　统计数据显示，我国大约有3亿儿童，作为药品消费的特殊群体，拥有近500亿元的市场潜力。

Statistics show,There are about 300 million children in China,As a special group of drug consumption,Has nearly 50 billion yuan market potential.

　　仅以感冒发烧为例，0～12岁儿童年平均发病率为3.72次，按每次发病5天计算，每天服用3包，即需感冒颗粒剂204.8亿包。儿童需要适合其生理特征的药品帮助其摆脱病痛的困扰，中国儿童药品市场实际容量巨大。

Only by the cold has a fever, for example,0 ~ 12 years old children's average annual incidence of a disease is 3.72 times,According to the five days every time calculation,Take 3 bag every day,That should be a cold granules of 20.48 billion bales.Children need for its physiological characteristics of the drug help them get rid of sickness trouble,Chinese children drug market actual capacity huge.

　　以广州市儿童医院来计算，2007年医院药房每个月零售价在400万左右，那么一年的销售量为14.6亿；该院每日就诊量在3000人左右，也就是说每个患儿每次看病大约要花44元左右，而全国约有3亿儿童，市场潜力有多么大毋庸置疑。

Guangzhou children's hospital to calculate,2007 every month hospital pharmacy retail price at around 4 million,So a year of sales for 1.46 billion;The hospital JiuZhenLiang daily in about 3000 people,That is every children every time the doctor takes about 44 yuan,And the national about 300 million children,How big market potential is no doubt.

　　然而目前该领域的市场情况却不容乐观。我国儿童药品种类十分缺乏，这不仅表现在本土儿童药品牌稀少、生产儿童用药的专业厂家寥寥无几，90%的市场份额被为数不多的外资企业瓜分，更令人担忧的是，统计表明，国内市场90%的药物都没有儿童剂型，儿科医生在用药时靠经验积累，安全隐患巨大。

But the field of the market situation is not optimistic.Our country children drug kinds very lack of,This is demonstrated not only in the local children's medicine brand few and far between/Children's medicine production of professional manufacturers very few,90% of the market share is one of the few foreign capital enterprise carve-up,More worrying is,Statistics show that,The domestic market, 90% of the drug are not children dosage form,Pediatrician in drug when rely on experience,Safety hidden trouble huge.

外资药企瓜分市场 Foreign medicine to divide up the market

　　安全性是儿童用药以及药品的第一要素。据了解，在美国等很多国家，儿童药品的开发做得比较好。

Safety is children's drugs and drug first elements.It is understood,In the United States and many other countries,Children's drug development to do better.

　　1997年之前，美国药品说明书很少标有儿童使用的信息。近年来，美国重点从法规层面推进企业在儿童药领域的研发。比如，在《食品药品现代化管理法》中用经济政策给予儿科用药6个月的市场保护期(即此期限内不允许其他企业仿制);对涉及治疗儿童罕见病的药品给予50%税收优惠、加快审批、7年的市场保护期等政策。

1997 years ago,American drug instruction rarely marked with children's use of information.In recent years,The United States focus from regulations in enterprise level in children in the field of medicine research and development.For example,in[The food and drug administration modernization]With economic policy to pediatric medicine six months of market protection(This period is not allowed other enterprise imitation);For those involved in the treatment of children with rare disease drug gives 50% preferential tax/Accelerate examining and approving the/Seven years of market protection policies.

　　此外，欧盟、日本、韩国等国家和地区也都从法律法规的制定上推动和促进儿童用药的研发生产。

In addition,The European Union/Japan/South Korea and other countries and regions is also from the formulation of laws and regulations on promoting and promote children's use of research and production.

　　据记者了解，在国外，一些厂家将成人用药通过成分或者配料、工艺的改变使其成为儿童用药，可以申请专利进行保护，从而在药品价格上通过高定价而得到补偿，这在很大程度上提高了药厂的积极性。但是在我国药厂这样做很难在药品价格上得到补偿，回报比较小。

According to reporter understanding,In foreign,Some manufacturers will adult medicine through the composition or ingredients/Technology changes make it become a children's medicine,You can apply for a patent protection,Thus in the drug price through the high pricing and compensated,This is largely improve the pharmaceutical factory's enthusiasm.But in China pharmaceutical factory to do so in the price of drugs is difficult to get compensation,Return small.

　　在良好的政策环境推动下，强生制药、赛诺菲安万特等跨国药企在儿童用药和疫苗市场领域雄踞全球。

In good policy environment push down,Johnson pharmaceutical/Sanofi-aventis multinational enterprises such as medicine in children's medicine and vaccine market field stands in the world.

　　感冒发烧是儿童常见病，也是儿童用药第一大类，据广州标点医药信息有限公司的数据，2011年上半年北京、上海、广州三地的儿童感冒化学药前两名分别是：上海强生制药的伪麻美沙芬滴剂(艾畅)、仁和药业的小儿氨酚烷胺颗粒(优卡丹)，两者市场份额平分秋色，都是16.1%。

The cold has a fever is a common disease of children,Is medicine for children first categories,According to the guangzhou punctuation medical information co., LTD. Of data,In the first half of 2011 Beijing/Shanghai/Guangzhou in the three children's cold chemical medicine before two are respectively:Shanghai Johnson pharmaceutical pseudo hemp dextromethorphan drops(YiChang)/Kernel and pharmaceutical of pediatric ammonia phenol paraffin amine particle(Optimal ·),Both market share even Steven,Is 16.1%.

　　不过，国家食品药品监督管理局将“优卡丹”等含盐酸金刚烷胺的儿童感冒药禁用于1岁以下儿童，致使优卡丹面临被要求修改说明书、缩小使用范围的窘境，可能会导致市场份额萎缩。市场分析人士称，此举意味着儿童用药监管将进一步收紧，给一向以安全性著称的外企扩大市场份额带来更多的机会。

but,State food and drug administration will"Optimal ·"YanSuanJinGangWanAn with children's cold medicine for children under the age of 1 ban,The optimal · face was asked to amend the description/Narrow the scope of use of dilemma,May lead to market share atrophy.Market analysts say,This means that children's medicine supervision will further tightening,To always with safety for foreign companies to expand market share to bring more opportunities.

　　在儿科医生眼中，外企的儿童药亦有着比本土药企产品更稳定的疗效及可控的副作用，同时外企产品的价格相对较高有利于提高药品收入，多重因素使外企儿童药在处方药市场胜出。

In the pediatric doctor eyes,The children also have a foreign medicine than native medicine enterprise products more stable curative effect and the controlled side effects,At the same time, foreign enterprise product price relatively high to improve drug income,Multiple factors make foreign children in medicine prescription drugs to win the market.

　　不仅在处方药市场如此，在保健品领域，外资和合资企业也表现得非常强势。在儿童维生素市场，90%以上的份额都被惠氏、罗氏、施贵宝几大企业所占据。

Not only in the prescription drug market so,In the field of health care products,Foreign capital and joint venture enterprise also played very strong.In children's vitamin market,More than 90% of the shares are wyeth/roche/A few big companies associated with the occupied.

推动发展需助力 To promote the development of power

　　“面对这么大市场，难道我们本土药企就不想跟外资企业拼一拼吗？就不想占领一定市场份额吗？儿童药品种类长期缺乏、儿童剂型药品短缺，根源还是研发成本所致。”一家不愿透露姓名的本土药企负责人说。

"In the face of such a big market,Can't we just don't want to local medicine enterprises with foreign capital enterprise spell a spell?He didn't want to occupy a certain market share?Children lack of long-term drug kinds/Children's dosage form drug shortage,Root or r&d cost caused by."A did not wish to be named, said the local drug enterprises.

　　据了解，一种专门适用于儿童的新药，从项目确定到研发，其费用往往不是一家药企能承担得起的。我国儿童药物的研发只能说刚刚起步，2004年才开放了儿童临床药物试验基地的审批，全国目前有29家医疗单位有资格做儿童药物试验，具体到各个儿科专业，还非常少。以呼吸系统药物为例，眼下只有上海、沈阳、无锡、温州等6地的一些医疗机构参与试验，可儿童呼吸系统疾病种类繁多，药品更新和淘汰速度又过快。

It is understood,A kind of special suitable for children's new drug,From the project to research and determine,Its cost is often not a medicine enterprises can afford the.Children in our country development of drugs can only say that has just started,2004 years to open a children's clinical drug test base of the examination and approval,The national there are 29 home medical units are qualified for children's drug test,Specific to each department of pediatrics professional,Also very little.To respiratory drugs, for example,The only Shanghai/shenyang/wuxi/Wenzhou, etc and some medical institutions to participate in test,Can children's respiratory diseases of various kinds,Drugs update and elimination speed and too fast.

　　“研发者和生产企业有可能投入巨大，却可能得不到相应的回报。这正是儿童药品长期缺乏的最主要原因。”业内专家称。

"Developers and production enterprise may devotion is huge,But may not get corresponding return.This is what children lack of long-term drug the most main reason."The expert inside course of study says.

　　药企作为市场主体，往往是以赢利为目的，注意规避风险，在研制儿童药品方面仅靠企业的自觉是够的。政府方面又不可能有大量精力完全主导儿童药品的研制和生产，最终这种责任还是需要生产企业来承担。

Medicine enterprises as the market main body,Often is for the purpose of profit,Pay attention to avoid risk,In the development of children in drugs only on the enterprises' the aware is enough.The government and impossible to have a lot of energy completely leading children drug development and production,In the end, this responsibility still need production enterprise to bear.

　　“这就需要通过一个科学合理的政策性激励举措，来调动药品生产企业的积极性。在儿童药品的研发环节，政府方面有必要明确规定相关政策补贴，在企业自主研制成功的儿童药品经临床检验可以推向市场后，对药品生产企业予以税收方面的减免，以及给予开发创新药物的公司和企业一个延长的知识产权保护期。”上述专家建议。

"This needs through a scientific and reasonable policy incentive measures,To mobilize the enthusiasm of the pharmaceutical production enterprise.In children's drug r&d link,The government it is necessary to specify related policy subsidy,In the enterprise independent research and successful children's drug by clinical examination can after the market,On pharmaceutical production enterprise shall be reduced taxes,And to develop innovative drug companies and enterprise for a prolonged intellectual property rights protection."The above expert advice.

　　据资料显示，英国政府就制定了一系列措施鼓励制药商开发儿童药品，如减免由监管机构收取的手续费，免费提供专家咨询等，以保证儿童药品的研发速度和市场供给，这都值得我们借鉴。本报记者 戴明阳

According to data display,The British government to develop a series of measures to encourage the drug manufacturer for a child to develop drugs,Such as derate regulators charged by the commission,Provide free expert consultation, etc,To ensure that children's drug research and development speed and the market supply,All this is worth our using for reference.Our reporter DaiMingYang